These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33660868)

  • 1. Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
    Introna A; Milella G; D'Errico E; Fraddosio A; Scaglione G; Ucci M; Ruggieri M; Simone IL
    Muscle Nerve; 2021 Jun; 63(6):905-909. PubMed ID: 33660868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
    Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
    J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen.
    Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N
    CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy.
    Dobelmann V; Roos A; Hentschel A; Della Marina A; Leo M; Schmitt LI; Maggi L; Schara-Schmidt U; Hagenacker T; Ruck T; Kölbel H
    J Neurol; 2024 Oct; 271(10):7000-7011. PubMed ID: 39240344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
    MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
    CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy.
    Panicucci C; Sahin E; Bartolucci M; Casalini S; Brolatti N; Pedemonte M; Baratto S; Pintus S; Principi E; D'Amico A; Pane M; Sframeli M; Messina S; Albamonte E; Sansone VA; Mercuri E; Bertini E; Sezerman U; Petretto A; Bruno C
    Cell Mol Life Sci; 2024 Sep; 81(1):393. PubMed ID: 39254732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
    Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
    J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy.
    Zhang Q; Hong Y; Brusa C; Scoto M; Cornell N; Patel P; Baranello G; Muntoni F; Zhou H
    Sci Rep; 2024 Oct; 14(1):23491. PubMed ID: 39379509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
    Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
    Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.
    Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.
    Garofalo M; Bonanno S; Marcuzzo S; Pandini C; Scarian E; Dragoni F; Di Gerlando R; Bordoni M; Parravicini S; Gellera C; Masson R; Dosi C; Zanin R; Pansarasa O; Cereda C; Berardinelli A; Gagliardi S
    Biol Direct; 2023 Sep; 18(1):57. PubMed ID: 37705059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.
    Schorling DC; Kölbel H; Hentschel A; Pechmann A; Meyer N; Wirth B; Rombo R; ; Sickmann A; Kirschner J; Schara-Schmidt U; Lochmüller H; Roos A
    Eur J Neurol; 2022 Jul; 29(7):2084-2096. PubMed ID: 35318785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources.
    Youn B; Proud CM; Wang N; Hou Q; Viscidi E; Eaton S; Paradis AD; Neville BA; Johnson NB
    Adv Ther; 2023 Mar; 40(3):1129-1140. PubMed ID: 36645543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
    Seo G; Kim S; Byun JC; Kwon S; Lee YJ
    Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.